Announcements Trials
Browse Landscape

Status

Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 10Expanded_access 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

trametinib 3dabrafenib 3talimogene laherparepvec 2pembrolizumab 2Nivolumab 2Ipilimumab 2ulixertinib 1tebentafusp 1pegilodecakin 1omaveloxolone 1methyl 5-aminolevulinate 1lifileucel 1efineptakin alfa 1cemiplimab 1balstilimab 1avelumab 1aldesleukin 1Rose Bengal 1Melphalan 1HhAntag691 1Cyclophosphamide 1Brentuximab Vedotin 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × lifileucel × Dermatologic × Clear all
NCT05398640 2026-04-20

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Iovance Biotherapeutics, Inc.

Available
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡